Early-Stage Phase I Services

Leveraging our experience with a scientifically grounded approach to progress your pharmacology studies

AXIS will be your clinical research partner for all your early-stage pharmacology enabling studies throughout your development program.

Our studies support NDA, 505(b)(2), Vaccines, and Biologics License Application (BLA) regulatory filings

We have experience conducting clinical studies of new chemical entities from a new biological entity, novel formulations, and complex generics.

We are accomplished at all early-stage studies required for drug development

Our onsite bioanalytical laboratory provides expedited analysis for dose-escalation studies

Our clinical units and bioanalytical laboratory are in the same building which elimates the need for shipping the samples.

We conduct our studies at our state-of-the-art Clinical Pharmacology Units (CPUs) in Minnesota

Over 40 studies a year are successfully conducted at the CPUs, with participant size ranging from 10 to 300+

120,000 sq ft facility
consisting of multiple flexible study units

234 participant
capacity

54
Hospital beds

Onsite
clinical safety lab

We have more than 130 staff with industry experience, various degree levels Masters, PhD, PharmD, and MD degrees 

Our team has experience with a wide array of drug-delivery methods

Our pharmacists will aid you in the development of a robust drug preparation, compounding, and dosing protocol and provide training to ensure consistent dosing.

What the industry is saying about AXIS

Scroll to see more

Interested in bringing your study to AXIS? Please send us an email or give us a call.